SPOTLIGHT -
EP. 1: Prognostic Factors and the Impact of New Therapies
EP. 2: Detecting Chromosomal Abnormalities in CLL
EP. 3: Front-Line Chemoimmunotherapy in CLL
EP. 4: Clinical Objectives in Chronic Lymphocytic Leukemia Treatment
EP. 5: The Value of CT Scans in Chronic Lymphocytic Leukemia
EP. 6: Chemoimmunotherapy in Chronic Lymphocytic Leukemia
EP. 7: CD-20 Antibodies in Chronic Lymphocytic Leukemia
EP. 8: The Role of Ofatumumab in the Treatment of CLL
EP. 9: Small-Molecule Inhibitors: Ibrutinib in CLL
EP. 10: Using Ibrutinib in Chronic Lymphocytic Leukemia
EP. 11: Pharmacovigilance with Ibrutinib in CLL
EP. 12: Mechanisms of Ibrutinib Resistance in CLL
EP. 13: Evaluating the Role of Idelalisib in CLL
EP. 14: Venetoclax in Chronic Lymphocytic Leukemia
EP. 15: Emerging Chronic Lymphocytic Leukemia Therapies
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
